Merck to Acquire Terns Pharmaceuticals for $6.7 Billion

Merck & Co. has agreed to acquire Terns Pharmaceuticals Inc. in a substantial deal valued at $6.7 billion. This acquisition is poised to significantly bolster Merck's existing pipeline, particularly in anticipation of patent expirations for a key cancer treatment. The move reflects Merck's strategy to enhance its portfolio with innovative therapies and strengthen its position in the competitive pharmaceutical market. Terns Pharmaceuticals brings a promising set of drug candidates that align with Merck's therapeutic focus.